Griffith University Aug 13 2025 A Phase 1 human clinical trial to treat chronic spinal cord injury, the first of its kind in the world, has commenced to test the efficacy and safety of a revolutionary new treatment using nasal cells. The Griffith University trial has been three decades in the making and involves taking olfactory ensheathing cells, which are specialised cells involved in our sense of smell, from the nose as they have numerous therapeutic properties for repairing and regenerating